Section 280E of the Internal Revenue Code is the single most consequential piece of tax law for cannabis investors. Enacted in 1982 in response to a convicted drug dealer claiming business expense deductions, Section 280E has become the bane of the legal cannabis industry, costing companies billions of dollars in excess taxes and fundamentally distorting how cannabis businesses are valued by investors.
The provision is straightforward in its language but devastating in its impact. Section 280E states that no deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business consists of trafficking in controlled substances which is prohibited by federal law. Because cannabis is classified as a Schedule I controlled substance under the Controlled Substances Act, every business that directly handles cannabis is subject to 280E — regardless of whether that business operates legally under state law.
The practical impact on cannabis companies is enormous. In a normal business, a company deducts cost of goods sold (COGS) and all ordinary and necessary business expenses — rent, salaries, marketing, insurance, administrative costs — from gross income to calculate taxable income. Under 280E, cannabis companies can deduct COGS but cannot deduct any other business expenses. This means a cannabis company is taxed on its gross profit rather than its operating profit, resulting in effective tax rates of 60-80% or higher.
Consider a concrete example. A cannabis MSO generates $100 million in revenue with $50 million in COGS and $40 million in operating expenses. In a normal industry, the company would have $10 million in pre-tax income and pay approximately $2.5 million in federal taxes (at a 25% rate). Under 280E, the same company has $50 million in gross profit that is essentially fully taxable because operating expenses cannot be deducted. The federal tax bill might be $20 million or more — turning what should be a modestly profitable company into one struggling with cash flow.
Cannabis companies have adopted various strategies to mitigate 280E's impact. Cost allocation to COGS is the most common approach: companies try to classify as many costs as possible as cost of goods sold (which remains deductible) rather than operating expenses. This is why cannabis companies' COGS figures often appear inflated relative to similar consumer product businesses. Corporate structure optimization involves separating plant-touching operations from non-plant-touching functions (management, marketing, IP) in different entities to shield some expenses from 280E. These strategies reduce but do not eliminate the 280E burden.
For investors, 280E creates a unique analytical challenge. Traditional financial metrics that depend on net income or operating income are distorted by 280E. A cannabis company's reported net income (or loss) is not comparable to companies in other industries. Investors must use pre-tax metrics — revenue, revenue growth, gross profit, gross margin, and adjusted EBITDA (before taxes) — to make meaningful comparisons. The Cannabismarketcap screener and ranking tools use these pre-tax metrics to enable fair cross-company comparison.
The investment thesis around 280E centers on its potential elimination. If cannabis is rescheduled from Schedule I to Schedule III, 280E would no longer apply because the provision only covers Schedule I and II substances. The financial impact would be immediate and dramatic: the billions of dollars currently paid in excess taxes would flow to the bottom line, dramatically increasing after-tax earnings and free cash flow for every plant-touching cannabis company.
Estimating the 280E upside for individual cannabis stocks is a valuable analytical exercise. Take a company's current adjusted EBITDA, subtract a normalized 25% tax rate (instead of the current 60-80%), and you get an approximation of post-280E earnings power. For many large MSOs, this exercise reveals that current stock prices imply the market does not fully believe 280E will be eliminated — or that the market is pricing in a low probability of rescheduling. If you believe rescheduling is likely, 280E-burdened stocks may be significantly undervalued.
The step-by-step approach to incorporating 280E analysis into your cannabis investing includes understanding which companies are most affected (plant-touching MSOs, LPs with US operations), quantifying the 280E tax burden for your holdings (compare gross profit to net income to see the tax impact), modeling the post-280E scenario for your holdings, and factoring the probability-weighted 280E upside into your valuation.
Companies that are already operating at or near profitability on an adjusted EBITDA basis stand to benefit the most from 280E elimination, because the tax savings flow directly to free cash flow. Companies that are still unprofitable on an adjusted EBITDA basis would see less immediate benefit, as they would have minimal taxable income even under 280E.
Common investor mistakes regarding 280E include ignoring it entirely and comparing cannabis financials to other industries, assuming 280E elimination is guaranteed when it depends on rescheduling, not understanding the difference between COGS deductibility (allowed) and operating expense deductibility (disallowed), and failing to distinguish between plant-touching companies affected by 280E and ancillary companies that are not.
Use this guide to properly frame your analysis of any US cannabis company that directly handles the plant. Section 280E is not just a tax footnote — it is the single largest financial headwind facing the cannabis industry and, if eliminated, the single largest catalyst for cannabis stock revaluation. Understanding 280E is not optional for serious cannabis investors.